Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,041.3
-79.3 (-2.54%)

 

  • STI Straits Times Index
    3,041.3
    -79.3 (-2.54%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,514.0
    3.4 (0.23%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    23,475.3
    -377.0 (-1.58%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,563.9
    1.2 (0.03%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    27,821.8
    -462.2 (-1.63%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,533.9
    -74.4 (-1.13%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 2,947.1M
  • Value: 3,865.3M
  • Rise: 100
  • Fall: 254
  • Unch: 403

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Lippo Malls Tr0.054-
Singtel2.360-0.050
Sembcorp Marine0.085+0.002
Genting Sing0.770-0.020
Medtecs Intl0.440-0.060
HGH0.020+0.001
ComfortDelGro1.370-0.060
CapLand IntCom T2.110-0.030
Ascendas Reit2.920-0.070
ThaiBev0.670-0.015

World Indices

World Indices
Name Last Change
Nasdaq 15,782.8 +291.2
HSI 23,475.3 -377.0
HSCEI 8,368.5 -129.8
Jakarta 6,533.9 -74.4
Nikkei 225 27,821.8 -462.2
SSE Comp 3,563.9 +1.2
Shanghai A 3,735.2 +1.3
Shanghai B 279.4 -1.1
KOSPI 2,839.0 -70.3

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Star Pharm^ STAR PHARMACEUTICAL LIMITED
Quotes 10 Minutes Delayed. No Trades for The Day
Last (SGD): 0.445 Change: - High: - Remarks: DL
Remarks legend:
RemarksDescriptionRemarksDescription
SuspSuspendedIMMImmediate Delivery
PLPending ListingPAPending Announcement
DLDelistedCTConditional Trading
CWConditional When IssueWIWhen Issue
BIBuyIn OnlyJAdjust
HTrading HaltCDCum Dividend
XDEx DividendCBCum Bonus
XBEx BonusCRCum Rights
XREx RightsCOCum Offer
XOEx OfferCECum Entitlement
XEEx EntitlementCICum Interest
XIEx InterestCACum All
XAEx AllSCScripless Conversion
CIRBCircuit Breaker TriggeredCIRHHalt due to Circuit Breaker Triggered
Change (%): - Low: -

Company Background

STAR Pharmaceutical Limited is engaged in the manufacture and sale of both Western and TCM-formulated prescription drugs, focusing primarily on antibiotics, cardiovascular drugs and cerebrovascular drugs. Our market is primarily in the PRC through our distribution network of approximately 240 distributors to hospitals, clinics and pharmacies. The Group also makes specialised drugs manufactured inhouse in various dosages and forms from powder injections, lyophilized powder injections, liquid injections to tablets, capsules and granules.

Click to show Stock Prices chart

Key Statistics

EPS (SGD) a 0.05068 Trailing EPS (SGD) b -0.04388 NAV (SGD) c 0.5652
PE a 8.781 Trailing PE d - Price / NAV c 0.7873
Dividend Yield (%) e - Cash In Hand (SGD) f 0.2419 Issued & Paid-up Shares g 45,875,000
Piotroski F Score 8 Market Cap (M) 20.414 Free Float (%) -
Return on Equity (ROE) (%) h n.m. Revenue Growth (%) TTM i 80.793
Net Earnings Growth (%) j 47.482 Net Debt/Equity k Net Cash
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Manufacturing - Pharmaceuticals: Major
Category Classification China / Medical & Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted based on Profit Attributable To Shareholders.
  2. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  3. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  4. Based on latest Full Year results announcement, adjusted for the current number of shares.
  5. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  6. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  7. Rounded to the nearest thousand. The figure pertains to the respective exchange the stock is listed on. Updated on 06 Dec 2019. Please click here for more information.
  8. Calculated based on Net Earnings / (Shareholders' Equity - Other Share Capital)
  9. Calculated based on (Current Year Revenue - Last Year Revenue) / Last Year Revenue
  10. Calculated based on (Current Year Earnings - Last Year Earnings) / Last Year Earnings
  11. Calculated based on (Long Term Debt + Short Term Debt - Cash and Short Term Investments)/(Shareholders' Equity - Other Share Capital)

Latest News

View All News

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days ---
10 Days ---
20 Days ---
Medium Term Return 3 Months --0.005
-1.11 %
6 Months -+0.275
+161.76 %
1 Year -+0.274
+160.23 %
Long Term Return 2 Years -+0.145
+48.33 %
3 Years -+0.295
+196.67 %
5 Years -+0.110
+32.84 %
Annualised Return Annualised --
+5.84 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Star Pharm^ SGX 20.414 8.781 - 0.7873 -
Industry China SGX 766.601 23.726 20.898 0.7239 3.476
Medical & Biotechnology SGX 1,036.754 19.134 16.263 1.4868 1.894
Pharmaceuticals: Major SGX 86.987 2431.015 115.115 3.5759 0.714
Local Peer Hyphens Pharma SGX 90.129 14.627 14.546 1.8171 2.067
Global Peer JOHNSON & JOHNSON NYSE 420,557.850 28.582 23.521 5.9847 2.491
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 195,410.893 24.208 19.926 3.4421 2.402
Global Peer MERCK & CO INC NYSE 189,167.647 26.768 26.284 5.2849 3.317
Global Peer PFIZER INC NYSE 294,114.388 30.586 15.334 3.8858 2.896
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 121,281.676 - - 3.2591 3.404
Global Peer ABBVIE INC NYSE 206,647.493 45.357 27.716 15.2508 4.134
Global Peer SANOFI SPON ADR ECH REP 1/2 ORD EUR2 LEVEL II NASDAQ 121,829.080 8.679 17.592 1.6245 2.808
Global Peer ELI LILLY AND COMPANY NYSE 243,768.339 39.357 40.816 31.4256 1.162
Global Peer GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 NYSE 104,056.797 14.115 17.536 5.0028 5.003
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 191,950.522 29.788 25.858 18.6286 1.242
Other Global Peers TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), WUXI APPTEC (HKEx), HANSOH PHARMA (HKEx), REATA PHARMACEUTICALS INC (NASDAQ), ALLAKOS INC (NASDAQ), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), CHINARES PHARMA (HKEx), INNOVENT BIO-B (HKEx), CMS (HKEx), HUTCHISON CHINA MEDITECH SPON ADS EACH REPR 5 ORD SHS (NASDAQ), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), HENLIUS-B (HKEx), JUNSHI BIO-B (HKEx), SSY GROUP (HKEx), RA PHARMACEUTICALS INC (NASDAQ), TRICIDA INC (NASDAQ), APELLIS PHARMACEUTICALS INC (NASDAQ), TURNING POINT THERAPEUTICS INC (NASDAQ), CHINAGRANDPHARM (HKEx), KARUNA THERAPEUTICS INC (NASDAQ), ZYMEWORKS INC (NYSE), AKCEA THERAPEUTICS INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), CONSTELLATION PHARMACEUTICALS INC (NASDAQ), CANSINOBIO-B (HKEx), Y-MABS THERAPEUTICS INC (NASDAQ), CSTONE PHARMA-B (HKEx), ATHENEX INC (NASDAQ), AMNEAL PHARMACEUTICALS INC (NYSE), PRINCIPIA BIOPHARMA INC (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), KRYSTAL BIOTECH INC (NASDAQ), UNITED LAB (HKEx), PHIBRO ANIMAL HEALTH CORP (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), QUANTERIX CORPORATION (NASDAQ), IGM BIOSCIENCES INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), PETIQ INC (NASDAQ), IGBB (Bursa), HUA MEDICINE-B (HKEx), FORTY SEVEN INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), AC IMMUNE SA (NASDAQ), PROVENTION BIO INC (NASDAQ), AKORN INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), FUSEN PHARM (HKEx), APTORUM GROUP LIMITED (NASDAQ), EVOLUS INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), BIOSPECIFICS TECHNOLOGIES CORP (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), BEYONDSPRING INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), 89BIO INC (NASDAQ), AMAG PHARMACEUTICS INC (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), UROVANT SCIENCES LTD (NASDAQ), LANNETT CO INC (NYSE), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), TOT BIOPHARM-B (HKEx), GRITSTONE ONCOLOGY INC (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), DAWNRAYS PHARMA (HKEx), FULCRUM THERAPEUTICS INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), XERIS PHARMACEUTICALS INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), AEGLEA BIOTHERAPEUTICS INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), OBSEVA SA (NASDAQ), AFT PHARMACEUTICALS LTD (ASX), OVID THERAPEUTICS INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), NEOLEUKIN THERAPEUTICS INC (NASDAQ), BIOMX INC (NYSE American), LOGICBIO THERAPEUTICS INC (NASDAQ), NC HEALTHCARE (HKEx), SOL GEL TECHNOLOGIES LTD (NASDAQ), GAMIDA CELL LTD (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), MUSTANG BIO INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), VERU INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), MILLENDO THERAPEUTICS INC (NASDAQ), CHARMACY PHAR (HKEx), AVENUE THERAPEUTICS INC (NASDAQ), MENLO THERAPEUTICS INC (NASDAQ), Merck Tbk. (IDX), PHASEBIO PHARMACEUTICALS INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), ESSA PHARMA INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), LIQUIDIA TECHNOLOGIES INC (NASDAQ), PALLA PHARMA LTD (ASX), KOTRA (Bursa), IMMUNIC INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), CNS PHARMACEUTICALS INC (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), SPRING BANK PHARMACEUTICALS INC (NASDAQ), EYENOVIA INC (NASDAQ), THE FS ALSEC ALPHASECTOR (NASDAQ), Phapros Tbk. (IDX), NOVAN INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), NEP INTERLONG (HKEx), MEDLAB CLINICAL LIMITED (ASX), CYCLERION THERAPEUTICS INC (NASDAQ), BAUDAX BIO INC (NASDAQ), IP (SET), MOLECULIN BIOTECH INC (NASDAQ), AGEX THERAPEUTICS INC (NYSE American), HOTH THERAPEUTICS INC (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), NOVA (Bursa), BIOHLDG (Bursa), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), EDESA BIOTECH INC (NASDAQ), TELIGENT INC NEW (NASDAQ), ZOMEDICA PHARMACEUTICALS CORP (NYSE American), NOXOPHARM LTD (ASX), ENTERA BIO LTD (NASDAQ), SINOLIFE UTD (HKEx), AERPIO PHARMACEUTICALS INC (NASDAQ), MMJ GROUP HOLDINGS LTD (ASX), RECCE PHARMACEUTICALS LTD (ASX), CHINA SXT PHARMACEUTICALS INC (NASDAQ), EXOPHARM LTD (ASX), CRESO PHARMA LTD (ASX), BRICKELL BIOTECH INC (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), KITOV PHARMA LTD SPON ADS EACH REP 1 ORD SHS (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), RACE ONCOLOGY LTD (ASX), TITAN PHARMACEUTICAL INC (NASDAQ), FARMAFORCE LTD (ASX), Merck Sharp Dohme Pharma Tbk. (IDX), NOVUS THERAPEUTICS INC (NASDAQ), SUDA PHARMACEUTICALS LTD (ASX), SIENNA BIOPHARMACEUTICALS INC (NASDAQ), GENPREX INC (NASDAQ), GEMPHIRE THERAPEUTICS INC (NASDAQ), FIJI KAVA LTD (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

More Information Available

More information is available to our subscribers, including:

  • Consensus Estimates
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.